[go: up one dir, main page]

GR3034523T3 - 3-Substituted oxindole derivatives as potassium channel modulators - Google Patents

3-Substituted oxindole derivatives as potassium channel modulators

Info

Publication number
GR3034523T3
GR3034523T3 GR20000402213T GR20000402213T GR3034523T3 GR 3034523 T3 GR3034523 T3 GR 3034523T3 GR 20000402213 T GR20000402213 T GR 20000402213T GR 20000402213 T GR20000402213 T GR 20000402213T GR 3034523 T3 GR3034523 T3 GR 3034523T3
Authority
GR
Greece
Prior art keywords
potassium channel
channel modulators
oxindole derivatives
substituted oxindole
substituted
Prior art date
Application number
GR20000402213T
Other languages
English (en)
Inventor
Piyasena Hewawasam
Nicholas A Meanwell
Valentin K Gribkoff
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of GR3034523T3 publication Critical patent/GR3034523T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
GR20000402213T 1995-06-07 2000-09-29 3-Substituted oxindole derivatives as potassium channel modulators GR3034523T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/477,047 US5565483A (en) 1995-06-07 1995-06-07 3-substituted oxindole derivatives as potassium channel modulators

Publications (1)

Publication Number Publication Date
GR3034523T3 true GR3034523T3 (en) 2000-12-29

Family

ID=23894292

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20000402213T GR3034523T3 (en) 1995-06-07 2000-09-29 3-Substituted oxindole derivatives as potassium channel modulators

Country Status (25)

Country Link
US (2) US5565483A (el)
EP (1) EP0747354B1 (el)
JP (1) JP4011135B2 (el)
KR (1) KR100432157B1 (el)
CN (1) CN1076348C (el)
AR (1) AR004493A1 (el)
AT (1) ATE195515T1 (el)
AU (1) AU707760B2 (el)
BR (1) BR1100180A (el)
CA (1) CA2176183C (el)
CZ (1) CZ289248B6 (el)
DE (1) DE69609772T2 (el)
DK (1) DK0747354T3 (el)
ES (1) ES2148685T3 (el)
GR (1) GR3034523T3 (el)
HU (1) HU222046B1 (el)
IL (1) IL118349A (el)
NO (1) NO304829B1 (el)
NZ (1) NZ286748A (el)
PL (1) PL184660B1 (el)
PT (1) PT747354E (el)
RU (1) RU2165925C2 (el)
SG (1) SG70572A1 (el)
TW (1) TW384284B (el)
ZA (1) ZA964327B (el)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW504504B (en) * 1996-11-26 2002-10-01 Bristol Myers Squibb Co 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators
HUP0002449A3 (en) * 1997-05-30 2001-12-28 Bristol Myers Squibb Company W Process for producing 3-fluoro oxindole derivatives and intermediates of the preparation
US5893085A (en) * 1997-06-10 1999-04-06 Phillips; Ronald W. Dynamic fuzzy logic process for identifying objects in three-dimensional data
US5972894A (en) * 1997-08-07 1999-10-26 Cytran, Inc. Peptides having potassium channel opener activity
WO1999009983A1 (en) * 1997-08-28 1999-03-04 Bristol-Myers Squibb Company 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators
JP2003527818A (ja) * 1998-08-14 2003-09-24 エラン ファーマシューティカルズ，インコーポレイテッド 新規なｅｓｋカリウムチャンネルのポリペプチドおよびポリヌクレオチドの組成物
RU2240998C2 (ru) 1998-12-04 2004-11-27 Бристол-Маерс Сквибб Компани Производные 3-замещенного 4-арилхинолин-2-она в качестве модуляторов калиевых каналов
DE69922997T2 (de) * 1998-12-04 2005-12-15 Neurosearch A/S Verwendung von isatinderivaten als ionenkanalaktivierende mittel
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
MXPA02001207A (es) * 1999-08-03 2002-07-30 Abbott Lab Abridores de canal de potasio.
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US6737420B2 (en) * 2000-03-23 2004-05-18 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
JP2004501192A (ja) * 2000-06-29 2004-01-15 ニューロサーチ、アクティーゼルスカブ Ｋｃｎｑカリウムチャネルモジュレーターとしての３−置換オキシインドール誘導体の使用方法
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
CA2410680A1 (en) 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
CA2425771A1 (en) * 2000-10-13 2002-04-18 Christopher G. Boissard Selective maxi-k- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6469042B1 (en) * 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
CA2438805A1 (en) * 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators of kcnq potassium channels
IL157313A0 (en) 2001-02-20 2004-02-19 Bristol Myers Squibb Co Modulators of kcnq potassium channels and uses thereof
AR033095A1 (es) * 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
CA2452039A1 (en) * 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
CA2479256A1 (en) * 2002-03-20 2003-10-02 Bristol-Myers Squibb Company Phosphate prodrugs of fluorooxindoles
WO2004002962A1 (en) * 2002-06-26 2004-01-08 Poseidon Pharmaceuticals A/S Novel benzimidazol-2-one derivatives and their use
TWI271402B (en) * 2002-10-15 2007-01-21 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
EP1553932A2 (en) * 2002-10-21 2005-07-20 Ramot at Tel Aviv University Ltd. Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators
KR100456679B1 (ko) * 2002-11-14 2004-11-10 현대모비스 주식회사 차량의 조수석 에어백의 장착구조
US6916937B2 (en) * 2003-02-03 2005-07-12 Bristol-Myers Squibb Company Carbohydrate prodrugs of fluorooxindoles
TW200508197A (en) * 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
EP1639091B1 (en) 2003-06-17 2012-12-05 California University Of Technology Regio- and enantioselective alkane hydroxylation with modified cytochrome p450
WO2005009993A1 (en) * 2003-07-15 2005-02-03 Smithkline Beecham Corporation Novel compounds
JPWO2005035498A1 (ja) * 2003-10-08 2006-12-21 住友製薬株式会社 含窒素二環性化合物の摂食調節剤としての用途
DK1689721T3 (da) * 2003-11-26 2010-09-20 Pfizer Prod Inc Aminopyrazolderivater som GSK-3-ihibitorer
US7169803B2 (en) * 2004-03-15 2007-01-30 Bristol-Myers Squibb Company N-substituted prodrugs of fluorooxindoles
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
GT200500321A (es) * 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
HU0500126D0 (en) * 2005-01-26 2005-04-28 Sanofi Aventis New compounds and process for their preparation
HU0500157D0 (en) * 2005-02-01 2005-04-28 Sanofi Aventis New compounds
HUP0500167A2 (en) * 2005-02-02 2007-03-28 Sanofi Aventis Optically active 4-chloro-3-(5-chloro-3-alkyl-2-oxo-2,3-dihydro-1h-indol-3-yl)benzoic acid derivatives and process for producing them
BRPI0610036A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp derivados de benzofuranil alcanamina e usos destes como agonìstico de 5-ht2c
TW200719886A (en) * 2005-04-22 2007-06-01 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
AU2006239920A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
WO2006116169A2 (en) * 2005-04-24 2006-11-02 Wyeth Methods for modulating bladder function
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
KR100983752B1 (ko) * 2005-07-13 2010-09-24 에프. 호프만-라 로슈 아게 5-ｈｔ6, 5-ｈｔ2ａ로서의 벤즈이미다졸 유도체
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
CA2644618A1 (en) * 2006-03-24 2007-10-04 Wyeth Methods for treating cognitive and other disorders
JP2009531434A (ja) * 2006-03-24 2009-09-03 ワイス 痛みの治療
PE20080010A1 (es) * 2006-03-24 2008-03-10 Wyeth Corp Derivados de diazepina para el tratamiento de la depresion y composiciones farmaceuticas que los comprenden
EP2069513A4 (en) * 2006-08-04 2012-03-21 California Inst Of Techn METHOD AND SYSTEMS FOR THE SELECTIVE FLUORINATION OF ORGANIC MOLECULES
US8252559B2 (en) * 2006-08-04 2012-08-28 The California Institute Of Technology Methods and systems for selective fluorination of organic molecules
US8802401B2 (en) * 2007-06-18 2014-08-12 The California Institute Of Technology Methods and compositions for preparation of selectively protected carbohydrates
CN101868443A (zh) 2007-09-20 2010-10-20 特拉维夫大学拉莫特有限公司 N-苯基邻氨基苯甲酸衍生物及其用途
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
US20100204247A1 (en) * 2007-10-04 2010-08-12 Duffy Joseph L N-substituted oxindoline derivatives as calcium channel blockers
KR100985286B1 (ko) * 2007-12-28 2010-10-04 주식회사 포스코 내지연파괴 특성이 우수한 고강도 고망간강 및 제조방법
EP2540295A1 (en) 2011-06-27 2013-01-02 Centre national de la recherche scientifique Compositions for the treatment of Fragile X syndrome
BR112017023200A2 (pt) * 2015-04-29 2018-08-07 Janssen Pharmaceutica Nv compostos de indolona e seu uso como moduladores do receptor de ampa
AU2016255434C1 (en) 2015-04-29 2021-09-23 Rapport Therapeutics, Inc. Azabenzimidazoles and their use as AMPA receptor modulators
CA3054315A1 (en) 2017-02-24 2018-08-30 Ovid Therapeutics Inc. Methods of treating seizure disorders
WO2019073471A1 (en) 2017-10-09 2019-04-18 Ramot At Tel-Aviv University Ltd. POTASSIUM TRPV1 AND IONIC CHANNEL MODULATORS AND USES THEREOF
US11819909B2 (en) * 2019-01-25 2023-11-21 Jfe Steel Corporation Method for manufacturing high-manganese steel cast slab and method for manufacturing high-manganese steel slab or steel sheet
CN110240558B (zh) * 2019-07-10 2022-05-27 上海华理生物医药股份有限公司 一种Flindokalner消旋体的新合成方法
KR102209406B1 (ko) * 2019-11-21 2021-01-29 주식회사 포스코 미세한 주조조직을 갖는 고망간강 및 그 제조방법과 이를 이용한 고망간 강판
EP3912625A1 (en) 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
WO2025233532A1 (en) 2024-05-10 2025-11-13 Les Laboratoires Servier Maxi-k potassium channel openers and therapeutic applications thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3114351A1 (de) * 1981-04-09 1982-11-04 Hoechst Ag, 6000 Frankfurt "oxindol-derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel mit neuroanaboler wirkung"
DE3529994A1 (de) * 1985-08-22 1987-02-26 Hoechst Ag Indolinonderivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
DE3803775A1 (de) * 1988-02-09 1989-08-17 Boehringer Mannheim Gmbh Neue substituierte lactame, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US5200422A (en) * 1990-09-24 1993-04-06 Neurosearch A/S Benzimidazole derivatives, their preparation and use
NZ239540A (en) * 1990-09-24 1993-11-25 Neurosearch As 1-phenyl benzimidazole derivatives and medicaments
CZ279488B6 (cs) * 1990-09-25 1995-05-17 Lonza A.G. Způsob mikrobiologické výroby hydroxylovaných heterocyklů
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
FR2714378B1 (fr) * 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
EP0747354B1 (en) 2000-08-16
TW384284B (en) 2000-03-11
DK0747354T3 (da) 2000-09-18
NO304829B1 (no) 1999-02-22
IL118349A (en) 2000-07-26
NO962232L (no) 1996-12-09
SG70572A1 (en) 2000-02-22
CZ289248B6 (cs) 2001-12-12
PL184660B1 (pl) 2002-11-29
CN1076348C (zh) 2001-12-19
HK1003301A1 (en) 1998-10-23
BR1100180A (pt) 2000-03-14
DE69609772D1 (de) 2000-09-21
ATE195515T1 (de) 2000-09-15
EP0747354A1 (en) 1996-12-11
NZ286748A (en) 1998-08-26
AR004493A1 (es) 1998-12-16
NO962232D0 (no) 1996-05-31
CN1144800A (zh) 1997-03-12
JP4011135B2 (ja) 2007-11-21
JPH08333336A (ja) 1996-12-17
ES2148685T3 (es) 2000-10-16
US5602169A (en) 1997-02-11
IL118349A0 (en) 1996-09-12
RU2165925C2 (ru) 2001-04-27
HU9601547D0 (en) 1996-08-28
PL314672A1 (en) 1996-12-09
PT747354E (pt) 2000-11-30
US5565483A (en) 1996-10-15
CZ161896A3 (en) 1997-03-12
KR970001324A (ko) 1997-01-24
HUP9601547A1 (en) 1997-09-29
CA2176183A1 (en) 1996-12-08
DE69609772T2 (de) 2001-04-12
CA2176183C (en) 2010-03-30
HU222046B1 (hu) 2003-04-28
ZA964327B (en) 1997-11-28
AU707760B2 (en) 1999-07-22
KR100432157B1 (ko) 2004-10-06
AU5475796A (en) 1996-12-19

Similar Documents

Publication Publication Date Title
HUP9601547A1 (en) 3-substituted oxindole derivatives as potassium channel modulators
AU2647597A (en) Oxindole derivatives
PL348039A1 (en) 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators
GB9718913D0 (en) Substituted oxindole derivatives
AU3110095A (en) Glutamate receptor
AU4400597A (en) Indole derivatives
ZA961697B (en) Indole derivatives.
EP1011677A4 (en) 4-ARYL-3-AMINOQUINOLEIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS
ZA9710561B (en) 4-Aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators
AU7450898A (en) Indole compounds
AU1671597A (en) Indole derivatives
AU6370196A (en) Indole derivatives
AU4224196A (en) Substituted indole derivatives
AU4355296A (en) Indole derivatives
AU6309396A (en) Novel use for pyrrole derivatives
AU5500596A (en) Pyrrolidinyl methyl indole salt
AU6370096A (en) Indole derivatives
AU6370296A (en) Indole derivatives
IL127261A0 (en) Heterocyclylmethylamino derivatives of cyclobutene-3,4- diones as potassium channel modulators
AU8128898A (en) Antibiotics containing indole derivatives
ZA96726B (en) Substituted indole derivatives
GB9523097D0 (en) Indole derivatives
AU6382398A (en) Smoking apparatus
HK1017884B (en) Pyrrolidinyl methyl indole salt
AUPP035797A0 (en) Improvements to smoking apparatus